Is PHG a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for PHG (PHG) rests on Margin recovery and cost discipline: Philips lifted its adjusted EBITA margin to 12.3 percent in 2025 and guides to 12.5 to 13.0 percent for 2026, driven by productivity savings, an innovation-led gross margin, and a leaner cost base. Revenue (2025) is ~EUR 17.8B (~$19B). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: China remains a drag, hurt by industry-wide anti-corruption measures, subdued demand, and share losses in imaging, and a single soft quarter there has moved the stock sharply in the past. Whether PHG is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Koninklijke Philips N.V. (Royal Philips) is a Netherlands-based health-technology company that generated roughly EUR 17.8 billion (about $19 billion) in 2025 sales across three segments: Diagnosis and Treatment (imaging systems, image-guided therapy, ultrasound), Connected Care (patient monitoring, hospital informatics, and its Respironics sleep and respiratory business), and Personal Health (electric shavers, toothbrushes, and mother-and-child care). US investors most commonly access it through the PHG American Depositary Receipt on the NYSE, which represents ordinary shares that also trade in Amsterdam; the ADR structure means currency moves between the euro and the dollar affect the quoted price and the dividend. The investment picture is a turnaround. After exiting its lighting and appliance roots to become a pure health-technology company, Philips spent recent years absorbing the 2021 Respironics device recall, related US litigation, and softness in China. In 2025 it returned to a reported net income of about EUR 897 million and lifted its adjusted EBITA margin to 12.3 percent, and it entered 2026 reiterating guidance for 3 to 4.5 percent comparable sales growth and a 12.5 to 13.0 percent adjusted EBITA margin. The story now hinges on whether order intake and margin gains can compound while the China market and legacy risks normalize.
What's the case for buying PHG?
1. Margin recovery and cost discipline
Philips lifted its adjusted EBITA margin to 12.3 percent in 2025 and guides to 12.5 to 13.0 percent for 2026, driven by productivity savings, an innovation-led gross margin, and a leaner cost base. Continued margin expansion is the clearest lever for earnings growth given only modest top-line growth. Progress here is what the turnaround thesis largely rests on.
2. Order intake and installed-base momentum
Comparable order intake grew 6 percent in Q1 2026, which supports future revenue in the capital-equipment-heavy Diagnosis and Treatment segment. Hospitals buying imaging systems then generate recurring service, software, and consumables revenue over the equipment life. Sustained order growth would signal that customers are returning after the recall-era disruption.
3. Diversified health-technology portfolio
The mix of hospital systems (imaging, monitoring), the Respironics respiratory franchise, and consumer Personal Health products (shavers, toothbrushes) gives Philips exposure to both capital cycles and steadier consumer demand. Personal Health grew about 8 percent in 2025, offsetting flat Diagnosis and Treatment. This breadth can smooth results across differing end-market cycles.
4. Cash generation and dividend
Philips produced roughly EUR 512 million of free cash flow in 2025 and proposed a dividend of EUR 0.85 per share, supporting a forward yield in the mid-single-digit-percent range on the ADR. Rebuilding cash flow toward its EUR 1.3 to 1.5 billion 2026 target would give the company more room to invest and return capital. The dividend is a meaningful part of the total-return case.
What are the risks to PHG?
China remains a drag, hurt by industry-wide anti-corruption measures, subdued demand, and share losses in imaging, and a single soft quarter there has moved the stock sharply in the past. The 2021 Respironics recall led to large US litigation; a roughly $1.1 billion personal-injury settlement and a medical-monitoring class-action resolution have reduced but not fully eliminated legal and reputational overhang. Tariffs and cost inflation pressure margins and partly offset productivity gains. As an ADR of a euro-reporting company, US investors bear currency risk between the euro and the dollar on both price and dividends. Competition from larger and well-capitalized rivals in imaging can pressure pricing and market share.
How is PHG valued? (as of JULY 2026)
Snapshot for PHG as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (2025): ~EUR 17.8B (~$19B)
- Net income (2025): ~EUR 897M
- Adjusted EBITA margin (2025): ~12.3%
- Market cap: ~$27B
- P/E (TTM): ~24x (forward ~16x)
- Forward dividend yield: ~3.7%
Philips trades at a trailing P/E in the low-20s that compresses to the mid-teens on a forward basis, reflecting expectations that margin recovery lifts earnings. The stock carried a market cap around $27 billion in mid-2026 on roughly $19 billion of sales, a price-to-sales near 1.3x. Figures are approximate, reported in euros, and converted to dollars at prevailing rates for the ADR.
How do you decide if PHG is a buy?
Rather than asking whether PHG is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold PHG indirectly through an index or sector ETF before adding more.
For the full picture, see the PHG stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about PHG against your real portfolio and see your actual exposure before deciding.
The bottom line on PHG
The bottom line: PHG's story right now is Margin recovery and cost discipline, with revenue (2025) at ~EUR 17.8B (~$19B). If you believe that narrative continues, the call is about sizing PHG sensibly and checking overlap with what you own; if you doubt it (the risk: china remains a drag, hurt by industry-wide anti-corruption measures, subdued demand, and share losses in imaging, and a single soft quarter there has moved the stock sharply in the past.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around PHG with Walnut
Use PHG as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is PHG a good stock to buy right now?
+
The case for PHG right now is Margin recovery and cost discipline, with revenue (2025) at ~EUR 17.8B (~$19B). If you believe that thesis holds, PHG is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is china remains a drag, hurt by industry-wide anti-corruption measures, subdued demand, and share losses in imaging, and a single soft quarter there has moved the stock sharply in the past. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does PHG do?
+
Koninklijke Philips N.V.
What are the main risks of PHG?
+
China remains a drag, hurt by industry-wide anti-corruption measures, subdued demand, and share losses in imaging, and a single soft quarter there has moved the stock sharply in the past. The 2021 Respironics recall led to large US litigation; a roughly $1.1 billion personal-injury settlement and a medical-monitoring class-action resolution have reduced but not fully eliminated legal and reputational overhang. Tariffs and cost inflation pressure margins and partly offset productivity gains. As an ADR of a euro-reporting company, US investors bear currency risk between the euro and the dollar on both price and dividends. Competition from larger and well-capitalized rivals in imaging can pressure pricing and market share.
What is PHG?
+
PHG is the NYSE-listed American Depositary Receipt (ADR) of Koninklijke Philips N.V., known as Royal Philips, a Dutch health-technology company. Each ADR represents ordinary shares that also trade in Amsterdam. Philips makes medical imaging, patient monitoring, and personal-health products.
Is PHG an American company?
+
No. Philips is headquartered in Amsterdam, the Netherlands, and reports in euros. US investors buy exposure through the PHG ADR on the NYSE, which tracks the euro-denominated shares, so currency moves between the euro and the dollar affect the ADR price and dividends.
What does Philips actually do now?
+
Philips is a pure health-technology company after exiting lighting and consumer appliances. It operates in three segments: Diagnosis and Treatment (imaging and image-guided therapy), Connected Care (patient monitoring and the Respironics respiratory business), and Personal Health (shavers, toothbrushes, and mother-and-child care).
How did Philips perform in 2025?
+
Philips reported roughly EUR 17.8 billion in 2025 sales with about 2 percent comparable growth, returned to a net income of about EUR 897 million, and raised its adjusted EBITA margin to 12.3 percent. It proposed a dividend of EUR 0.85 per share and generated about EUR 512 million of free cash flow.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell PHG; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.